South Korea Biobank Market Size, Share, and COVID-19 Impact Analysis, By Sample Storage (Blood, Cells & Tissue, and Others), By Application (Regenerative Medicines, Life Sciences, and Others), By Settings (Academic Medical Institutes and Pharmaceutical & Biotechnology Companies), and South Korea Biobank Market Industry Trend, Forecasts to 2035

 South Korea Biobank Market is expected to grow from USD 1498.5 million in 2024 to USD 5434.3 million by 2035, growing at a CAGR of 12.42% during the forecast period of 2025-2035.

South Korea Biobank Market Insights Forecasts to 2035

• The South Korea Biobank Market Size Was Estimated at USD 1498.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 12.42% from 2025 to 2035
• The South Korea Biobank Market Size is Expected to Reach USD 5434.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Biobank Market is anticipated to reach USD 5434.3 million by 2035, growing at a CAGR of 12.42% from 2025 to 2035. The process of establishing diverse repositories for the gathering, storing, and sharing of human samples, including blood, plasma, serum, urine, tissues, cells, and more, is known as a biobank.  Over the years, the biobanking industry has seen remarkable change and is currently expanding significantly.

Market Overview

The biobank market involves the collection, storage, and management of biological samples like blood, tissues, and cells for research and clinical use. Biobanks support advancements in personalized medicine, drug development, and disease research by providing high-quality, well-characterized samples. The improved diagnostic accuracy, accelerated medical research, and enhanced development of targeted therapies. Growing prevalence of chronic diseases and demand for precision medicine present significant market opportunities. In South Korea, government initiatives promoting biomedical research, funding infrastructure development, and establishing national biobank networks are driving market growth. Supportive policies and collaborations between academic institutions, pharmaceutical companies, and healthcare providers further enhance biobank accessibility and utilization, fostering innovation in healthcare and biotechnology sectors.

Report Coverage

This research report categorizes the market for South Korea biobank market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea biobank market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea biobank market.

Driving Factors

The increasing demand for personalized medicine and precision healthcare, which rely on high-quality biological samples for research and diagnosis. Rising prevalence of chronic and genetic diseases fuels the need for extensive biobanking. Advances in biotechnology and data analytics enhance sample utilization and research outcomes.

Restraining Factors

High operational costs associated with establishing and maintaining biobanks, including expenses for specialized equipment, storage facilities, and skilled personnel, pose significant financial barriers, particularly for smaller institutions or in resource-constrained settings. 

Market Segmentation

The South Korea biobank market share is classified into sample storage, application, and settings.

• The blood segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea biobank market is segmented by sample storage into blood, cells & tissue, and others. Among these, the blood segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The critical role of blood samples in diagnostics, disease research, and personalized medicine. Blood is the most commonly collected and easily accessible biological material, essential for genetic, proteomic, and biomarker studies. The increasing prevalence of chronic diseases and growing demand for large-scale population health studies are driving blood sample storage.

• The regenerative medicines segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea biobank market is segmented by application into regenerative medicines, life sciences, and others. Among these, the regenerative medicines segment dominated a share in 2024 and is expected to grow at a significant CAGR during the forecast period. Growing investments in stem cell research and advanced therapies targeting chronic and degenerative diseases. Biobanks provide essential high-quality biological samples, such as stem cells and tissues, critical for developing regenerative treatments. Increasing government support, favorable regulations, and rising demand for personalized medicine further fuel growth.

• The academic medical institutes segment dominated the share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea biobank market is segmented by settings into academic medical institutes and pharmaceutical & biotechnology companies. Among these, the academic medical institutes segment dominated the share in 2024 and is expected to grow at a significant CAGR during the forecast period. Their pivotal role in collecting, managing, and utilizing biological samples for research and clinical applications. These institutes have well-established infrastructure, expertise, and collaborations that support extensive biobanking activities. Their focus on advancing medical research, education, and personalized medicine drives high demand for biobank resources.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea biobank market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Korea National Institute of Health (KNIH)
• Seoul National University Hospital Biobank
• Korea Biobank Network (KBN)
• Celltrion
• Samsung Medical Center Biobank
• Asan Medical Center Biobank
• Korea Advanced Institute of Science and Technology (KAIST)
• Genexine
• Macrogen
• Green Cross Corporation
• ToolGen
• Helixmith
• Others

Recent Developments:

• In May 2024, South Korea-based CHA Bio Group and CIC, a Cambridge, US-based global leader in building and operating innovation communities, have signed a Memorandum of Understanding (MoU) to establish an open innovation centre focused on research and innovation around the CGB (Cell Gene Biobank).

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea biobank market based on the below-mentioned segments:

South Korea Biobank Market, By Sample Storage

• Blood
• Cells & Tissue
• Others

South Korea Biobank Market, By Application

• Regenerative Medicines
• Life Sciences
• Others

South Korea Biobank Market, By Settings

• Academic Medical Institutes
• Pharmaceutical & Biotechnology Companies